WO2008057337A3 - Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema - Google Patents

Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema Download PDF

Info

Publication number
WO2008057337A3
WO2008057337A3 PCT/US2007/022902 US2007022902W WO2008057337A3 WO 2008057337 A3 WO2008057337 A3 WO 2008057337A3 US 2007022902 W US2007022902 W US 2007022902W WO 2008057337 A3 WO2008057337 A3 WO 2008057337A3
Authority
WO
WIPO (PCT)
Prior art keywords
edema
occurance
delaying
inhibitors
preventing
Prior art date
Application number
PCT/US2007/022902
Other languages
French (fr)
Other versions
WO2008057337A2 (en
Inventor
Boerk Balkan
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Original Assignee
Novartis Ag
Boerk Balkan
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Boerk Balkan, David Grenville Holmes, Thomas Edward Hughes, Edwin Bernard Villhauer filed Critical Novartis Ag
Priority to JP2009535293A priority Critical patent/JP2010508348A/en
Priority to MX2009004627A priority patent/MX2009004627A/en
Priority to AU2007318059A priority patent/AU2007318059A1/en
Priority to BRPI0717874-3A priority patent/BRPI0717874A2/en
Priority to CA002668162A priority patent/CA2668162A1/en
Priority to EP07853026A priority patent/EP2079469A2/en
Publication of WO2008057337A2 publication Critical patent/WO2008057337A2/en
Publication of WO2008057337A3 publication Critical patent/WO2008057337A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

A method to prevent, delay the progression or reduce, the occurrence of edema, comprising administering a therapeutically effective amount of a DPP-IV inhibitor, or pharmaceutically acceptable salt thereof, to a patient in need thereof.
PCT/US2007/022902 2006-11-01 2007-10-30 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema WO2008057337A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009535293A JP2010508348A (en) 2006-11-01 2007-10-30 Use of dipeptidyl peptidase IV inhibitors to prevent, delay or alleviate edema
MX2009004627A MX2009004627A (en) 2006-11-01 2007-10-30 Use of organic compounds.
AU2007318059A AU2007318059A1 (en) 2006-11-01 2007-10-30 Use of Dipeptidyl peptidase IV inhibitors for preventing, delaying or reducing the occurance of edema
BRPI0717874-3A BRPI0717874A2 (en) 2006-11-01 2007-10-30 USE OF ORGANIC COMPOUNDS
CA002668162A CA2668162A1 (en) 2006-11-01 2007-10-30 Use of organic compounds
EP07853026A EP2079469A2 (en) 2006-11-01 2007-10-30 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86381606P 2006-11-01 2006-11-01
US60/863,816 2006-11-01

Publications (2)

Publication Number Publication Date
WO2008057337A2 WO2008057337A2 (en) 2008-05-15
WO2008057337A3 true WO2008057337A3 (en) 2008-10-16

Family

ID=39365028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022902 WO2008057337A2 (en) 2006-11-01 2007-10-30 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema

Country Status (9)

Country Link
EP (1) EP2079469A2 (en)
JP (1) JP2010508348A (en)
KR (1) KR20090075747A (en)
CN (1) CN101557811A (en)
AU (1) AU2007318059A1 (en)
BR (1) BRPI0717874A2 (en)
CA (1) CA2668162A1 (en)
MX (1) MX2009004627A (en)
WO (1) WO2008057337A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
WO2006047248A1 (en) * 2004-10-25 2006-05-04 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
WO2007035665A1 (en) * 2005-09-20 2007-03-29 Novartis Ag Use of a dpp-iv inhibitor to reduce hypoglycemic events

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US20050021092A1 (en) * 2003-06-09 2005-01-27 Yun Anthony Joonkyoo Treatment of conditions through modulation of the autonomic nervous system
WO2006047248A1 (en) * 2004-10-25 2006-05-04 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
WO2007035665A1 (en) * 2005-09-20 2007-03-29 Novartis Ag Use of a dpp-iv inhibitor to reduce hypoglycemic events

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHREN B ET AL: "Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 27, no. 12, 1 December 2004 (2004-12-01), pages 2874 - 2880, XP002412952, ISSN: 0149-5992 *
PANINA G: "The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.", DIABETES, OBESITY & METABOLISM SEP 2007, vol. 9 Suppl 1, September 2007 (2007-09-01), pages 32 - 39, XP002480989, ISSN: 1462-8902 *
ROY ET AL: "Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: Preclinical efficacy and safety in db/db mice", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 81, no. 1, 12 June 2007 (2007-06-12), pages 72 - 79, XP022114319, ISSN: 0024-3205 *
SITAGLIPTIN STUDY 019 GROUP ROSENSTOCK ET AL: "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 28, no. 10, 15 November 2006 (2006-11-15), pages 1556 - 1568, XP005793112, ISSN: 0149-2918 *

Also Published As

Publication number Publication date
BRPI0717874A2 (en) 2013-10-29
AU2007318059A1 (en) 2008-05-15
MX2009004627A (en) 2009-05-22
EP2079469A2 (en) 2009-07-22
CA2668162A1 (en) 2008-05-15
CN101557811A (en) 2009-10-14
KR20090075747A (en) 2009-07-08
WO2008057337A2 (en) 2008-05-15
JP2010508348A (en) 2010-03-18

Similar Documents

Publication Publication Date Title
WO2007149797A3 (en) Use of organic compounds
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
HUS1400009I1 (en) Administration of dipeptidyl peptidase inhibitors
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
MX2007004020A (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure.
WO2008127975A3 (en) Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
TW200716081A (en) Combination of organic compounds
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
MX350745B (en) Methods for treating fibromyalgia syndrome.
WO2005072713A3 (en) Cholinesterase inhibitors for treating inflammation
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
IL200653A0 (en) Weekly administration of dipeptidyl peptidase inhibitors
WO2008109681A3 (en) Methods and intermediates for synthesis of selective dpp-iv inhibitors
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors
TNSN08383A1 (en) Renin inhibitors for the treatment of hypertension
WO2008057337A3 (en) Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema
WO2007136615A3 (en) Combination cancer therapy
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
WO2006133231A3 (en) Treatment for neurodegenerative diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780040135.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1994/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007318059

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007853026

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007318059

Country of ref document: AU

Date of ref document: 20071030

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004627

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009535293

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2668162

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097011038

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009120573

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853026

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0717874

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090430